An observational study in Systemic Inflammatory Response Syndrome, sponsored by Phoenix Children's Hospital. Recruiting at 2 sites in United States. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2025-11-12.
Sponsored by Phoenix Children's Hospital · Observational
The goal of this study is to demonstrate the sensitivity and specificity of detecting circulating micro RNA (miRNA) biomarkers in pediatric septic patients. It will also follow expression and modulation of levels in response to therapy in comparison to current biomarkers.
This study will aid in the evaluation of determining the accuracy of these miRNAs in pediatric patients and help in establishing pilot data for additional studies in the future. The testing will include blood samples, urine samples and buccal swabs from patients who meet eligibility at 5 time points to analyze biomarkers. Study participants will receive standard of care with antimicrobials and any additional appropriate cardiovascular or respiratory support per the clinical team. The samples will collected and stored at -80 until analysis can be performed. In addition to, during the course of the hospitalization, the enrolled patient will have data collected to calculate severity scores, including updated Pediatric Risk of Mortality (PRISM III) scores and simplified Therapeutic Intervention Scoring System(TISS-28) scores. All patient information will be de-identified. A standard procedure manual will be developed detailing the methods for data collection and entry. Data will be recorded in a de-identified manner on a Microsoft Excel database on a secure institutional server by the institutional staff. Data will then be analyzed to determine correlation of biomarkers to morbidity and mortality for these patients.
Children ages 1-18 who are Immune-competent (no previous chronic medical conditions) patients being admitted to the PICU at PCH with concerns for sepsis or those developing sepsis during their admission to the hospital who require care in the PICU.
Exclusion Criteria:
Previously healthy, non-immunocompromised patients, between the ages of 1 and 18, who are being admitted to the PCH PICU for sepsis or septic shock, will be enrolled. Blood samples, urine samples and buccal swabs will be obtained from these patients at 5 time points to analyze biomarkers. Study participants will receive standard of care with antimicrobials and any additional appropriate cardiovascular or respiratory support per the clinical team. The samples will collected and stored at -80 until analysis can be performed. In addition to, during the course of the hospitalization, the enrolled patient will have data collected to calculate severity scores, including PRISM scores and TISS-28 scores. All patient information will be de-identified. A standard procedure manual will be developed detailing the methods for data collection and entry.
Procedure: miRNA in Sepsis
Healthy non-immunocompromised patients between 1-18 years old
miRNA in Sepsis
Risk of Mortality
Will compare PRISM 3 scores from baseline to hospital discharge.
Time frame: Duration of hospital stay, an expected average of 3 weeks
Organ Failure
Will compare sequential organ failure assessment (SOFA) scores throughout hospitalization.
Time frame: Duration of hospital stay, an expected average of 3 weeks
Organ Dysfunction
Will compare pediatric multiple organ dysfunction scores (PMODS) throughout hospitalization
Time frame: Duration of hospital stay, an expected average of 3 weeks
Patient acuity
Will assess TISS-28 scores throughout hospitalization.
Time frame: Duration of hospital stay, an expected average of 3 weeks
Plan to share: Undecided — Principal investigator is undecided if he plans on having a DTA or MTA.
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Systemic Inflammatory Response Syndrome→
Phoenix Children's Hospital